GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
E

Evelo Biosciences EVLO · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Evelo Biosciences

Its shares trade under the ticker EVLO. It has been listed since 9 May 2018.

Evelo Biosciences, Inc. operates as a clinical stage biotechnology company. The company is headquartered in Cambridge, Massachusetts. The company went IPO on 2018-05-09. The firm develops monoclonal microbes that are orally-delivered compositions of specific strains of naturally occurring microbes derived from a single clone. Its principal product candidates include EDP1066, EDP1815, and EDP1503 that are in the pre-clinical development stage. EDP1066 and EDP1815 are monoclonal microbial product candidates that are developed to treat inflammatory diseases that include psoriasis, atopic dermatitis, rheumatoid arthritis, and ulcerative colitis. EDP1503 is the Company's product candidate developed under oncology portfolio to treat diseases, such as colorectal cancer, renal cell carcinoma, and melanoma among others.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
9 May 2018
Employees
98

Leadership

Pay as last reported

  • Mr. Craig JalbertPresident, Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer, Company Secretary, Director, since 2023
  • Dr. Mark BodmerChief Scientific Officer, President of Research and Development$1.2m
  • Mr. Daniel CharGeneral Counsel, Secretary
  • Dr. Duncan McHaleChief Medical Officer$1.2m
  • Mr. Mark PlinioChief Commercial Officer

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
45
Environment
18
Social
74
Governance
42
Carbon reduction policy
No
Human rights policy
No

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Evelo Biosciences employs 98 full-time staff members in its operations.
  • The company developed monoclonal microbes as orally-delivered compositions for treatment.
  • EDP1066 and EDP1815 target inflammatory diseases like psoriasis and arthritis.

Weaknesses

  • EDP1066, EDP1815, and EDP1503 remain in the pre-clinical development stage.
  • The firm lacks approved products generating commercial revenue currently.
  • Reliance on three specific candidates limits immediate product diversity.

Opportunities

  • EDP1503 targets oncology diseases such as colorectal cancer and melanoma.
  • EDP1815 addresses atopic dermatitis and rheumatoid arthritis patient needs.
  • Ulcerative colitis represents a significant market for EDP1066 development.

Threats

  • Competitors may develop superior treatments for inflammatory skin diseases.
  • Regulatory hurdles could delay the pre-clinical to clinical transition.
  • Oncology trials for EDP1503 face high failure risks currently.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.